Episodes

  • Pharmaceutical Executive Daily: Novartis Acquires Excellergy Inc.

    Pharmaceutical Executive Daily: Novartis Acquires Excellergy Inc.
    Mar 27 2026
    In today's Pharmaceutical Executive Daily, Novartis agrees to acquire Excellergy for up to $2 billion to advance a next-generation anti-IgE therapy while Otsuka moves to acquire Transcend Therapeutics in a deal valued at up to $1.225 billion, the FDA approves two first-of-their-kind therapies in Novo Nordisk's once-weekly basal insulin Awiqli and Rocket Pharmaceuticals' gene therapy Kresladi for a rare pediatric immune disease, and a new commentary argues that orphan drug manufacturers should be proactively evaluating risk contracting as a hedge against an emerging downward pricing environment.
    Show more Show less
    3 mins
  • Pharmaceutical Executive Daily: Trump Administration Misses Deadline to Nominate Permanent CDC Director

    Pharmaceutical Executive Daily: Trump Administration Misses Deadline to Nominate Permanent CDC Director
    Mar 26 2026
    In today's Pharmaceutical Executive Daily, the Trump administration misses a statutory deadline to nominate a permanent CDC director, leaving the agency in continued leadership limbo, the FDA grants accelerated approval to Denali Therapeutics' Avlayah as the first therapy designed to cross the blood-brain barrier and treat the neurological manifestations of Hunter syndrome, and a new Pharmaceutical Executive commentary breaks down what CMS's updated ASP reporting requirements mean for Part B drug manufacturers ahead of a key April deadline.
    Show more Show less
    3 mins
  • Pharmaceutical Executive Daily: FDA Issues Warning Letter to ImmunityBio

    Pharmaceutical Executive Daily: FDA Issues Warning Letter to ImmunityBio
    Mar 25 2026
    In today's Pharmaceutical Executive Daily, the FDA issues a warning letter to ImmunityBio over misleading promotional claims about its bladder cancer therapy Anktiva, Merck agrees to acquire Terns Pharmaceuticals in a $6.7 billion deal while Shionogi moves to take full ownership of the Shionogi-Apnimed Sleep Science joint venture, and a new commentary examines the structural pricing problem sitting at the center of the GLP-1 access debate.
    Show more Show less
    3 mins
  • Pharmaceutical Executive Daily: Bayer Shares Drop After Inclusive Capital Offloads Remaining Stake

    Pharmaceutical Executive Daily: Bayer Shares Drop After Inclusive Capital Offloads Remaining Stake
    Mar 24 2026
    In today's Pharmaceutical Executive Daily, Bayer shares briefly dip after activist investor Inclusive Capital offloads its remaining stake at a loss, Quotient Therapeutics enters a multi-year research collaboration with Merck to discover novel drug targets in inflammatory bowel disease, and Gilead Sciences agrees to acquire privately held Ouro Medicines in a deal valued at up to $2.18 billion.
    Show more Show less
    2 mins
  • Pharmaceutical Executive Daily: Pfizer Warns Shareholders to Reject Mini-Tender Offer

    Pharmaceutical Executive Daily: Pfizer Warns Shareholders to Reject Mini-Tender Offer
    Mar 23 2026
    In today's Pharmaceutical Executive Daily, Pfizer warns shareholders to reject an unsolicited mini-tender offer from Tutanota LLC seeking to purchase up to one million shares at a potentially below-market price, the FDA grants expanded approval to Rhythm Pharmaceuticals' Imcivree as the first approved treatment for acquired hypothalamic obesity, and a new commentary makes the case that AI-powered roleplay data is an untapped source of commercial intelligence for pharma field teams.
    Show more Show less
    3 mins
  • Pharmaceutical Executive Daily: FDA Approves Wegovy HD

    Pharmaceutical Executive Daily: FDA Approves Wegovy HD
    Mar 20 2026
    In today's Pharmaceutical Executive Daily, Novartis agrees to acquire a pan-mutant-selective inhibitor from Synnovation Therapeutics in a deal worth up to $3 billion while Collegium moves to acquire Azstarys from Corium Therapeutics, the FDA grants accelerated approval to Wegovy HD, a higher-dose version of Novo Nordisk's semaglutide injection, supported by Phase III data showing roughly 21% mean weight loss, and an analysis on agentic AI and what it means for commercial operations in life sciences.
    Show more Show less
    3 mins
  • The Ron Lanton Report: When Policy Becomes a Capital Event

    The Ron Lanton Report: When Policy Becomes a Capital Event
    Mar 20 2026
    The episode explores how regulatory signals across drug approvals, trade policy, AI governance, and drug pricing shape business strategy and investor decisions before formal rules are ever finalized.
    Show more Show less
    10 mins
  • Pharmaceutical Executive Daily: Analysis on TrumpRx List Pricing

    Pharmaceutical Executive Daily: Analysis on TrumpRx List Pricing
    Mar 19 2026
    In today's Pharmaceutical Executive Daily, a new analysis finds that TrumpRx is listing prices for roughly a third of its featured drugs higher than what patients in the United Kingdom pay, two biotech companies focused on next-generation T-cell engager therapies close significant funding rounds, and Pharmaceutical Executive sits down with Jeanne Marrazzo of the Infectious Diseases Society of America on the worsening U.S. measles outbreak and what it means for the future of vaccine confidence.
    Show more Show less
    3 mins